Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 8/20 | 0.32 |
| ▸ | BRAF | P15056 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23901463 | 0.78 | ALDH1A1 (0.39) | MAPK1ALDH1A1HSD17B10 | |
| SCHEMBL23901591 | 0.75 | RAB9A (0.43) | MAPK1ALDH1A1HSD17B10 | |
| SCHEMBL23901524 | 0.75 | IRAK4 (0.41) | IRAK4RAF1MAPK1ALDH1A1HSD17B10 | |
| SCHEMBL23901521 | 0.73 | CD38 (0.39) | — | |
| SCHEMBL23901679 | 0.73 | RAF1 (0.34) | IRAK4RAF1CNR2PIK3CDPIK3CB | |
| SCHEMBL23901553 | 0.72 | TYRO3 (0.34) | CNR2 | |
| SCHEMBL23901674 | 0.72 | LMNA (0.38) | IRAK4CNR2MAPK1ALDH1A1HSD17B10 | |
| SCHEMBL19452075 | 0.71 | IRAK4 (0.36) | IRAK4RAF1BRAFCNR2MAPK1 | |
| SCHEMBL23901677 | 0.71 | L3MBTL1 (0.45) | IRAK4MAPK1ALDH1A1HSD17B10 | |
| SCHEMBL23901684 | 0.70 | CNR1 (0.38) | CNR2MAPK1PIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309661-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309661-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, GBA2 | IRAK4 1349/4885KDM5B 542/4885RAF1 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.